Sugi Predict

Sugi Predict / Compounds / SCHEMBL5750431

SCHEMBL5750431

SCHEMBL5750431

C#CC1(O)CCN(C(=O)OCc2ccccc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.59
▸ NPC1 O15118 3/20 0.59
▸ RAB9A P51151 3/20 0.59
▸ MEN1 O00255 2/20 0.57
▸ KMT2A Q03164 2/20 0.57
▸ NPSR1 Q6W5P4 2/20 0.57
▸ CYP2C19 P33261 1/20 0.56
▸ OPRD1 P41143 1/20 0.52
▸ OPRK1 P41145 1/20 0.52
▸ KDM1A O60341 2/20 0.49
▸ HTT P42858 1/20 0.48
▸ ENPP2 Q13822 1/20 0.47
▸ ATXN2 Q99700 1/20 0.47
▸ NOS2 P35228 1/20 0.47
▸ HDAC1 Q13547 3/20 0.47
▸ HDAC6 Q9UBN7 3/20 0.47
▸ HDAC8 Q9BY41 1/20 0.47
▸ HDAC3 O15379 2/20 0.47
▸ HDAC2 Q92769 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5748204 0.86 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL25845763 0.84 MEN1 (0.54) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL566838 0.82 MEN1 (0.61) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL6827246 0.82 MEN1 (0.61) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL3271874 0.82 MEN1 (0.51) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL934263 0.81 MEN1 (0.64) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL5748101 0.81 MEN1 (0.54) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL3970912 0.81 MEN1 (0.76) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL4814264 0.81 MEN1 (0.76) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL7393652 0.81 MEN1 (0.76) SMN1; SMN2NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119823124-A Compounds for targeted degradation of BRD9 C4医药公司 2025-04-15 — — CN disclosed
US-20250084081-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 C4 THERAPEUTICS, INC. (US) 2025-03-13 — — US disclosed
CN-115279370-B Compounds for targeted degradation of BRD9 C4医药公司 2025-01-10 — — CN disclosed
US-12157735-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2024-12-03 — — US disclosed
US-12049464-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2024-07-30 — — US disclosed
US-20240051953-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 C4 THERAPEUTICS, INC. (US) 2024-02-15 — — US disclosed
US-11691972-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2023-07-04 — — US disclosed
US-11691972-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2023-07-04 — — US disclosed
US-20230060334-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 C4 THERAPEUTICS, INC. (US) 2023-03-02 — — US disclosed
EP-4114392-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 C4 Therapeutics, Inc. (US) 2023-01-11 — — EP disclosed
CN-115279370-A Compounds for targeted degradation of BRD9 C4医药公司 2022-11-01 — — CN disclosed
US-20220098194-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 C4 THERAPEUTICS, INC. (US) 2022-03-31 — — US disclosed
US-9777020-B2 Furo-3-carboxamide derivatives and methods of use ABBVIE INC. (US) 2017-10-03 — — US disclosed
US-20150210720-A1 FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE ABBVIE INC. 2015-07-30 — — US disclosed
EP-1419155-B1 PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM PLC (GB) 2006-11-08 — — EP disclosed
US-20040198756-A1 Medicaments SMITHKLINE BEECHAM PLC (GB) 2004-10-07 — — US disclosed
EP-1419155-A2 PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM PLC (GB) 2004-05-19 — — EP disclosed
WO-2003010138-A2 PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM PLC (GB) 2003-02-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230060334-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 BRD9, BRD1, BRWD1 SMN1; SMN2 377/4885NPC1 1253/4885RAB9A 86/4885
US-20220098194-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 BRD9, BRD1, BRWD1 SMN1; SMN2 377/4885NPC1 1253/4885RAB9A 86/4885
US-20040198756-A1 Medicaments PIGO, PSAP, CD68 SMN1; SMN2 3564/4885NPC1 2141/4885RAB9A 4271/4885
US-20150210720-A1 FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE NTRK2, MUSK, NTRK3 SMN1; SMN2 833/4885NPC1 1851/4885RAB9A 2556/4885
US-12157735-B2 Compounds for targeted degradation of BRD9 BRD9, BRD1, BRWD1 SMN1; SMN2 377/4885NPC1 1253/4885RAB9A 86/4885
US-12049464-B2 Compounds for targeted degradation of BRD9 BRD9, BRD1, BRWD1 SMN1; SMN2 377/4885NPC1 1253/4885RAB9A 86/4885
US-20240051953-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 BRD9, BRD1, BRWD1 SMN1; SMN2 377/4885NPC1 1253/4885RAB9A 86/4885
US-20250084081-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 BRD9, BRD1, BRWD1 SMN1; SMN2 377/4885NPC1 1253/4885RAB9A 86/4885
US-11691972-B2 Compounds for targeted degradation of BRD9 BRD9, BRD1, BRWD1 SMN1; SMN2 725/4885NPC1 1766/4885RAB9A 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.